PMC:7170415 / 15143-16372 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"225","span":{"begin":387,"end":391},"obj":"Gene"},{"id":"226","span":{"begin":149,"end":161},"obj":"Gene"},{"id":"227","span":{"begin":65,"end":75},"obj":"Species"},{"id":"228","span":{"begin":192,"end":197},"obj":"Species"},{"id":"229","span":{"begin":346,"end":356},"obj":"Species"},{"id":"230","span":{"begin":485,"end":495},"obj":"Species"},{"id":"231","span":{"begin":561,"end":574},"obj":"Species"}],"attributes":[{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"Gene:43740578"},{"id":"A226","pred":"tao:has_database_id","subj":"226","obj":"Gene:43740575"},{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"Tax:2697049"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"Tax:9606"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"Tax:2697049"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"Tax:2697049"},{"id":"A231","pred":"tao:has_database_id","subj":"231","obj":"Tax:11118"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T15","span":{"begin":162,"end":166},"obj":"Body_part"},{"id":"T16","span":{"begin":206,"end":210},"obj":"Body_part"},{"id":"T17","span":{"begin":225,"end":228},"obj":"Body_part"},{"id":"T18","span":{"begin":357,"end":360},"obj":"Body_part"},{"id":"T19","span":{"begin":371,"end":374},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T64","span":{"begin":65,"end":69},"obj":"Disease"},{"id":"T65","span":{"begin":346,"end":350},"obj":"Disease"},{"id":"T66","span":{"begin":485,"end":489},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T142","span":{"begin":26,"end":29},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T143","span":{"begin":30,"end":33},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T144","span":{"begin":162,"end":166},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T145","span":{"begin":192,"end":197},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T146","span":{"begin":206,"end":210},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T147","span":{"begin":297,"end":309},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T148","span":{"begin":410,"end":415},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T149","span":{"begin":589,"end":590},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T150","span":{"begin":660,"end":663},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T151","span":{"begin":926,"end":933},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T152","span":{"begin":935,"end":937},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T153","span":{"begin":1070,"end":1072},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T154","span":{"begin":1088,"end":1091},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T155","span":{"begin":1138,"end":1140},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T14","span":{"begin":111,"end":116},"obj":"Chemical"},{"id":"T15","span":{"begin":175,"end":177},"obj":"Chemical"},{"id":"T16","span":{"begin":317,"end":322},"obj":"Chemical"}],"attributes":[{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_50406"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_17997"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_50406"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T15","span":{"begin":198,"end":205},"obj":"http://purl.obolibrary.org/obo/GO_0004526"},{"id":"T16","span":{"begin":387,"end":391},"obj":"http://purl.obolibrary.org/obo/GO_0003968"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T113","span":{"begin":0,"end":82},"obj":"Sentence"},{"id":"T114","span":{"begin":83,"end":255},"obj":"Sentence"},{"id":"T115","span":{"begin":256,"end":421},"obj":"Sentence"},{"id":"T116","span":{"begin":422,"end":655},"obj":"Sentence"},{"id":"T117","span":{"begin":656,"end":939},"obj":"Sentence"},{"id":"T118","span":{"begin":940,"end":1074},"obj":"Sentence"},{"id":"T119","span":{"begin":1075,"end":1229},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the United States, the CDC has developed the most widely used SARS–CoV-2 assay. The kit contains PCR primer–probe sets for 2 regions of the viral nucleocapsid gene (N1 and N2), and for the human RNase P gene to ensure the RNA extraction was successful. This assay differs from the World Health Organization primer–probe sets, which target the SARS–CoV-2 RNA-dependent RNA polymerase (RdRP) and envelope (E) genes (25). Both assays have high analytic sensitivity and specificity for SARS–CoV-2, with minimal cross-reactivity with other circulating strains of coronaviruses, and both use a cycle threshold of less than 40 as the criterion for positivity. The CDC kit may be used by state public health laboratories, other laboratories determined by the state to be qualified, and clinical laboratories that meet the regulatory requirements of the Clinical Laboratories Improvement Amendment (CLIA) to perform high-complexity testing (27). Dozens of laboratories have applied for Emergency Use Authorization (EUA) from the FDA for their own laboratory-developed assays (34). The FDA also has granted an EUA for several commercial assays (35), further expanding the ability of clinical laboratories to use these platforms (Table)."}